Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) have been given a consensus rating of “Buy” by the sixteen brokerages that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $98.89.

Several equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. Leerink Swann assumed coverage on shares of Agios Pharmaceuticals in a research report on Monday. They set a “market perform” rating and a $80.00 target price for the company. Guggenheim assumed coverage on shares of Agios Pharmaceuticals in a research report on Monday, September 17th. They set a “neutral” rating for the company. ValuEngine lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 11th. Finally, Cann reissued a “hold” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, September 5th.

In other Agios Pharmaceuticals news, insider Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, July 5th. The shares were sold at an average price of $83.50, for a total transaction of $250,500.00. Following the transaction, the insider now directly owns 60,196 shares of the company’s stock, valued at $5,026,366. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Maraganore sold 13,555 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $72.75, for a total transaction of $986,126.25. Following the completion of the transaction, the director now directly owns 38,609 shares in the company, valued at $2,808,804.75. The disclosure for this sale can be found here. Insiders have sold 28,627 shares of company stock worth $2,212,296 over the last three months. Insiders own 3.02% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of AGIO. Wells Fargo & Company MN increased its stake in shares of Agios Pharmaceuticals by 2.4% in the first quarter. Wells Fargo & Company MN now owns 72,776 shares of the biopharmaceutical company’s stock worth $5,952,000 after buying an additional 1,711 shares during the period. Rhumbline Advisers increased its stake in shares of Agios Pharmaceuticals by 11.1% in the first quarter. Rhumbline Advisers now owns 50,151 shares of the biopharmaceutical company’s stock worth $4,101,000 after buying an additional 5,029 shares during the period. State Board of Administration of Florida Retirement System increased its stake in shares of Agios Pharmaceuticals by 11.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 61,221 shares of the biopharmaceutical company’s stock worth $5,007,000 after buying an additional 6,238 shares during the period. Swiss National Bank increased its stake in shares of Agios Pharmaceuticals by 24.3% in the first quarter. Swiss National Bank now owns 87,060 shares of the biopharmaceutical company’s stock worth $7,120,000 after buying an additional 17,000 shares during the period. Finally, M&T Bank Corp purchased a new position in shares of Agios Pharmaceuticals in the first quarter worth $293,000. 93.63% of the stock is currently owned by institutional investors.

Agios Pharmaceuticals stock traded up $0.21 during mid-day trading on Friday, hitting $76.10. 253,398 shares of the company traded hands, compared to its average volume of 442,810. Agios Pharmaceuticals has a one year low of $51.62 and a one year high of $99.82. The firm has a market cap of $4.40 billion, a PE ratio of -11.29 and a beta of 1.77.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.62) by $0.43. Agios Pharmaceuticals had a negative net margin of 462.08% and a negative return on equity of 51.71%. The business had revenue of $40.40 million during the quarter, compared to analyst estimates of $12.47 million. During the same period in the previous year, the business posted ($1.78) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was up 257.5% on a year-over-year basis. analysts anticipate that Agios Pharmaceuticals will post -6.01 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Article: How to Use a Moving Average for TradingĀ 

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.